Importantly, improved outcome in mice receiving the combined anti-OPN antibody treatment in early and late acute phase was associated with a highly significant reduction of osteopontin and CD44 receptor expression (Figs. 3 , 4 ), and osteopontin-CD44 receptor interaction (Supplementary Figs.
← all excerpts
Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke.
1
—
—